ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder

Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5‐Year Update

C. Holly A. Andrilla, Tessa E. Moore, Davis G. Patterson et al. · The Journal of Rural Health · 2018 · 320 citations

Pharmacy, Health Administration, Health Services Research +15

Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment

Rebecca L. Haffajee, Amy S. B. Bohnert, Pooja Lagisetty · American Journal of Preventive Medicine · 2018 · 255 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacotherapy +17

Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities

Sarah E. Wakeman, Michael L. Barnett · New England Journal of Medicine · 2018 · 174 citations

Nursing, Family Medicine, Pharmacotherapy +17

Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder

Kevin Fiscella, Sarah E. Wakeman, Leo Beletsky · JAMA Psychiatry · 2018 · 160 citations

Medicine, Otolaryngology, Surgery +10

Deaths Attributable to Methadone vs Buprenorphine in France

Marc Auriacombe · JAMA · 2001 · 131 citations

Medicine, Internal Medicine, Oncology +6